$1.21
+0.05 (+4.31%)
Open$1.20
Previous Close$1.16
Day High$1.22
Day Low$1.15
52W High$3.20
52W Low$1.00
Volume—
Avg Volume62.6K
Market Cap12.91M
P/E Ratio—
EPS$-2.11
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,706.6% upside
Current
$1.21
$1.21
Target
$33.96
$33.96
$19.62
$33.96 avg
$35.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 227.0K | 590.4K | 1.55M |
| Net Income | -31,155,262 | -72,925,190 | 361.3K |
| Profit Margin | -13,700.0% | -13,015.0% | 23.4% |
| EBITDA | -30,891,690 | -76,325,371 | 534.5K |
| Free Cash Flow | — | — | 193.8K |
| Rev Growth | -61.6% | -61.6% | +15.5% |
| Debt/Equity | — | — | 1.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |